{"created":"2023-11-15T07:18:15.712359+00:00","id":2000419,"links":{},"metadata":{"_buckets":{"deposit":"737ee7d5-53f2-40a6-9092-f89d30e3c8f7"},"_deposit":{"created_by":42,"id":"2000419","owners":[42],"pid":{"revision_id":0,"type":"depid","value":"2000419"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:02000419","sets":["14:2667:1697004343623"]},"author_link":[],"item_1693381679919":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"report","resourceuri":"http://purl.org/coar/resource_type/c_93fc"}]},"item_30001_bibliographic_information17":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicNumberOfPages":"6","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2022)","bibliographic_titleLang":"ja"}]}]},"item_30001_creator2":{"attribute_name":"研究代表者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"34419","affiliationNameIdentifierScheme":"kakenhi"}],"affiliationNames":[{"affiliationName":"近畿大学","affiliationNameLang":"ja"},{"affiliationName":"Kindai University","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"西野, 将矢","creatorNameLang":"ja"},{"creatorName":"NISHINO, MASAYA","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"40709664","nameIdentifierScheme":"e-Rad"}]}]},"item_30001_description8":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"本邦癌死因第一位の肺癌のなかでEGFR遺伝子変異陽性肺癌に対する分子標的治療の有効性が確立されて久しい。その中でもEGFRエクソン20挿入変異に関しては有効な治療法が確立されていない。エクソン20挿入変異肺がん細胞モデルを樹立し、それらに対して有効な分子標的治療薬を模索すること、耐性化機序を明らかとすることを目的とした。poziotinib、tarloxotinibがこれら肺癌モデル細胞に対して有効であり、かつENUを用いた耐性化二次変異誘発にて、EGFR　T790MとC797Sを耐性化二次変異として同定した。さらに新規薬剤mobocertinibに関しても評価を行い、有効であることを示した。","subitem_description_language":"ja","subitem_description_type":"Abstract"},{"subitem_description":"Lung cancer is the leading cause of cancer death in Japan, and the efficacy of molecular targeted therapy for EGFR mutation-positive lung cancer has long been established. Among these, no effective therapy has been established for EGFR exon 20 insertion mutations. We established exon 20 mutant lung cancer cell models and sought to identify effective molecular targeted therapies against them and to clarify the mechanism of resistance. poziotinib and tarloxotinib were found to be effective against these lung cancer cell models, and resistant secondary mutation induction using ENU We identified EGFR T790M and C797S as resistant secondary mutations by ENU induction. In addition, a novel drug, mobocertinib, was also evaluated and shown to be effective.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"研究分野：肺癌","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_30001_file22":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"20K16398seika.pdf","format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://kindai.repo.nii.ac.jp/record/2000419/files/20K16398seika.pdf"},"version_id":"d978ce0c-6d0a-450f-80d4-c99e140763e5"}]},"item_30001_funding_reference15":{"attribute_name":"助成情報","attribute_value_mlt":[{"subitem_award_numbers":{"subitem_award_number":"20K16398","subitem_award_uri":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20K16398/"},"subitem_award_titles":[{"subitem_award_title":"EGFRエクソン20挿入変異陽性肺がんに対する治療戦略の新展開","subitem_award_title_language":"ja"},{"subitem_award_title":"New Therapeutic Strategies for EGFR Exon 20 Insertion Mutation-Positive Lung Cancer","subitem_award_title_language":"en"}],"subitem_funder_names":[{"subitem_funder_name":"独立行政法人日本学術振興会","subitem_funder_name_language":"ja"},{"subitem_funder_name":"Japan Society for the Promotion of Science","subitem_funder_name_language":"en"}]}]},"item_30001_language10":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_30001_subject7":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"EGFR遺伝子変異陽性肺癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"エクソン20挿入変異","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"分子標的治療薬","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_30001_title0":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"EGFRエクソン20挿入変異陽性肺がんに対する治療戦略の新展開","subitem_title_language":"ja"},{"subitem_title":"New Therapeutic Strategies for EGFR Exon 20 Insertion Mutation-Positive Lung Cancer","subitem_title_language":"en"}]},"item_30001_version_type12":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_title":"EGFRエクソン20挿入変異陽性肺がんに対する治療戦略の新展開","item_type_id":"40001","owner":"42","path":["1697004343623"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-11-15"},"publish_date":"2023-11-15","publish_status":"0","recid":"2000419","relation_version_is_last":true,"title":["EGFRエクソン20挿入変異陽性肺がんに対する治療戦略の新展開"],"weko_creator_id":"42","weko_shared_id":-1},"updated":"2024-10-23T00:48:13.745470+00:00"}